LUCENTIS

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug LUCENTIS contains one active pharmaceutical ingredient (API):

1	Ranibizumab UNII ZL1R02VT79 - RANIBIZUMAB
	Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A). It binds with high affinity to the VEGF-A isoforms, thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2. Binding of VEGF-A to its receptors leads to endothelial cell proliferation and neovascularisation, as well as vascular leakage, all of which are thought to contribute to the progression of the neovascular form of age-related macular degeneration, pathologic myopia and CNV or to visual impairment caused by either diabetic macular oedema or macular oedema secondary to RVO in adults and retinopathy of prematurity in preterm infants.
	Read more about Ranibizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LUCENTIS Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01LA04	Ranibizumab	S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10138N, 10373Y, 10374B, 11471R, 11480F, 11975G, 11981N, 1382R
BR	Câmara de Regulação do Mercado de Medicamentos	526515080085503, 526518030092303, 526529502157216
CA	Health Products and Food Branch	02296810, 02425629
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	27.954-04-08
EE	Ravimiamet	1299933, 1664669
ES	Centro de información online de medicamentos de la AEMPS	106374003, 106374004
FI	Lääkealan turvallisuus- ja kehittämiskeskus	387375, 538757
FR	Base de données publique des médicaments	64339586
GB	Medicines & Healthcare Products Regulatory Agency	140395, 246076
HK	Department of Health Drug Office	55638, 63860, 65166
IL	מִשְׂרַד הַבְּרִיאוּת	6036, 8634
IT	Agenzia del Farmaco	037608015, 037608027, 037608039, 037608041, 037608054
JP	医薬品医療機器総合機構	1319403A1036, 1319403G1020
LT	Valstybinė vaistų kontrolės tarnyba	1071582, 1075419, 1084489
NL	Z-Index G-Standaard	16016610
NL	Z-Index G-Standaard, PRK	116424, 87092
NZ	Medicines and Medical Devices Safety Authority	12442
PL	Rejestru Produktów Leczniczych	100165086
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W51850002
SG	Health Sciences Authority	13411P, 14772P
TN	Direction de la Pharmacie et du Médicament	10283321H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699504770254, 8699504770353
US	FDA, National Drug Code	50242-080, 50242-082
ZA	Health Products Regulatory Authority	41/15.4/0860